Kezdőlap・Részvénylista・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Lezárt

SzektorEgészségügy

9.02 2.5

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

8.75

Maximum

9.02

Fő mutatók
By Trading Economics
Bevétel	-1.1B -722M
Értékesítés	-250M 156M
P/E Szektor átlag	7.603 68.51
Egy részvényre jutó nyereség	0.14
Profit margin	-461.478
Munkavállalók	435
EBITDA	-966M -700M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+148.47% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. aug. 5.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-99M 2.2B
Előző nyitás	6.52
Előző zárás	9.02

BioCryst Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 4. 19:36 UTC

Correlated Moves

BioCryst Pharmaceuticals Inc shares are higher today, supported by gains in the biotechnology sector. The stock remains above its earlier low despite recent trends.

2026. aug. 3. 19:56 UTC

BioCryst Pharmaceuticals Inc shares are lower today, continuing a downward trend since Friday. The broader market is seeing gains, contrasting with BioCryst's performance.

2026. júl. 31. 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading. No specific news was identified to explain this movement, reflecting routine performance since Friday's close.

2026. júl. 30. 20:09 UTC

BioCryst Pharmaceuticals shares are lower amid broader market volatility following mixed economic signals, including rising jobless claims and disappointing GDP growth.

2026. júl. 29. 19:35 UTC

BioCryst Pharmaceuticals Inc shares are lower amid a declining market, with no specific company news identified to explain the movement during today's session.

2026. júl. 28. 23:06 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, continuing an upward trend from Tuesday's close, despite an earlier session pullback.

2026. júl. 27. 20:01 UTC

BioCryst Pharmaceuticals Inc shares are trading higher in Monday's session, reflecting notable strength despite remaining near the lower end of their one-month trading range.

2026. júl. 24. 21:01 UTC

BioCryst Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market trends following a decline in the Nasdaq influenced by negative earnings reports.

2026. júl. 22. 21:51 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline amid significant volatility in U.S. markets and lack of specific news.

2026. júl. 21. 17:46 UTC

BioCryst Pharmaceuticals Inc shares are higher today, continuing an upward trend since Monday. The stock remains below its 20-day moving average.

2026. júl. 20. 19:16 UTC

Correlated Moves

Shares lower amid decline in Biotechnology sub-sector and SPDR ETF.

Társak összehasonlítása

Árváltozás

BioCryst Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

148.47% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 21.89 USD 148.47%

Magas 32 USD

Alacsony 12 USD

9 Wall Street elemző 12 hónapos célárain alapulva a(z)BioCryst Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

9 ratings

Vétel

Tartás

Eladás

9 Wall Street elemző célárain alapulva a(z)BioCryst Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.